BHC · Insider Trading
Bausch Health Companies Inc
Every open-market purchase and sale reported by BHC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Sandra Leung | Director | A | +5,789 | +$33.75K |
| 2026-10-02 | Amy B Wechsler | Director | A | +1,179 | +$6.87K |
| 2026-10-02 | John Paulson | Director | A | +10,720 | +$62.50K |
| 2026-08-20 | Aimee J. Lenar | President, US Pharma | Sell | −36,827 | −$258.89K |
| 2026-07-20 | Aimee J. Lenar | President, US Pharma | F | −5,260 | −$25.41K |
| 2026-07-17 | Aimee J. Lenar | President, US Pharma | F | −23,395 | −$114.40K |
| 2026-07-15 | Steven Hyosig Lee | SVP, Controller & CAO | F | −3,125 | −$14.84K |
| 2026-07-02 | Sandra Leung | Director | A | +6,845 | +$33.75K |
| 2026-07-02 | Amy B Wechsler | Director | A | +1,394 | +$6.87K |
| 2026-07-02 | John Paulson | Director | A | +12,677 | +$62.50K |
| 2026-05-26 | Frank D. Lee | Director | A | +45,871 | — |
| 2026-05-26 | Christian A Garcia | Director | A | +45,871 | — |
| 2026-05-26 | Michael Goettler | Director | A | +45,871 | — |
| 2026-05-26 | Sandra Leung | Director | A | +45,871 | — |
| 2026-05-26 | Robert N Power | Director | A | +45,871 | — |
| 2026-05-26 | Eiry Roberts | Director | A | +45,871 | — |
| 2026-05-26 | Sarah B Kavanagh | Director | A | +45,871 | — |
| 2026-05-26 | Amy B Wechsler | Director | A | +45,871 | — |
| 2026-05-26 | John Paulson | Director | A | +45,871 | — |
| 2026-05-20 | Frank D. Lee | Director | Sell | −24,456 | −$132.80K |
| 2026-04-02 | Sandra Leung | Director | A | +5,946 | +$32.11K |
| 2026-04-02 | Amy B Wechsler | Director | A | +1,273 | +$6.87K |
| 2026-04-02 | John Paulson | Director | A | +11,574 | +$62.50K |
| 2026-03-03 | Thomas Appio | Chief Executive Officer | MIXED | −1,304,660 | −$7.76M |
| 2026-03-03 | Jean-Jacques Charhon | EVP, CFO | F | −49,060 | −$290.93K |
| 2026-03-03 | Seana Carson | EVP, General Counsel | MIXED | −192,497 | −$1.14M |
| 2026-02-27 | Thomas Appio | Chief Executive Officer | MIXED | +698,923 | −$703.67K |
| 2026-02-27 | Steven Hyosig Lee | SVP, Controller & CAO | A | +45,868 | — |
| 2026-02-27 | Seana Carson | EVP, General Counsel | MIXED | +171,751 | −$244.46K |
| 2026-02-27 | Jean-Jacques Charhon | EVP, CFO | MIXED | +240,078 | −$217.30K |
| 2026-02-27 | Aimee J. Lenar | EVP, US Pharma | MIXED | +139,561 | −$106.17K |
| 2026-02-11 | Seana Carson | EVP, General Counsel | A | +137,922 | — |
| 2026-02-11 | Thomas Appio | Chief Executive Officer | A | +1,137,862 | — |
| 2026-01-02 | Amy B Wechsler | Director | A | +989 | — |
| 2026-01-02 | Sandra Leung | Director | A | +4,586 | — |
| 2026-01-02 | John Paulson | Director | A | +8,992 | — |
| 2025-11-28 | PAULSON & CO. INC. | 10%+ Owner | Buy | +2,500,000 | +$15.62M |
| 2025-10-06 | John Paulson | Director | — | — | — |
| 2025-10-02 | John Paulson | Director | A | +9,689 | — |
| 2025-10-02 | Sandra Leung | Director | A | +3,673 | — |
| 2025-10-02 | Amy B Wechsler | Director | A | +1,065 | — |
| 2025-09-08 | Seana Carson | EVP, General Counsel | MIXED | −64,707 | −$475.06K |
| 2025-08-22 | Frank D. Lee | Director | Sell | −15,912 | −$121.89K |
| 2025-08-14 | John Paulson | Director | Buy | +34,721,118 | +$312.49M |
| 2025-08-13 | John Paulson | Director | Buy | +3,243,049 | +$21.27M |
| 2025-07-29 | Sandra Leung | Director | A | +30,149 | — |
| 2025-07-29 | Michael Goettler | Director | A | +30,149 | — |
| 2025-07-18 | Aimee J. Lenar | EVP, US Pharma | A | +30,847 | — |
| 2025-07-16 | Aimee J. Lenar | EVP, US Pharma | F | −22,736 | −$145.97K |
| 2025-07-15 | Steven Hyosig Lee | SVP, Controller & CAO | A | +27,371 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John Paulson | Director | 73,696,831 | $599.52M |
| PAULSON & CO. INC. | 10%+ Owner | 73,255,869 | $595.94M |
| Thomas Appio | Chief Executive Officer | 3,453,236 | $28.09M |
| Seana Carson | EVP, General Counsel | 782,932 | $6.37M |
| Jean-Jacques Charhon | EVP, CFO | 706,478 | $5.75M |
| Aimee J. Lenar | President, US Pharma | 334,853 | $2.72M |
| Amy B Wechsler | Director | 316,158 | $2.57M |
| Robert N Power | Director | 300,594 | $2.45M |
| Sarah B Kavanagh | Director | 282,230 | $2.30M |
| Steven D Miller | Director | 239,224 | $1.95M |
| Brett Icahn | Director | 220,280 | $1.79M |
| John S Barresi | SVP, Controller & CAO | 197,364 | $1.61M |
| Richard Mulligan | Director | 155,616 | $1.27M |
| Christian A Garcia | Director | 135,578 | $1.10M |
| Sandra Leung | Director | 102,859 | $836.76K |
| Frank D. Lee | Director | 95,210 | $774.53K |
| Michael Goettler | Director | 76,020 | $618.42K |
| Steven Hyosig Lee | SVP, Controller & CAO | 70,114 | $570.38K |
| Eiry Roberts | Director | 45,871 | $373.16K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BHC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.